Exploiting bacterial DNA gyrase as a drug target: current state and perspectives by Collin, Frédéric et al.
MINI-REVIEW
Exploiting bacterial DNA gyrase as a drug target:
current state and perspectives
Frédéric Collin & Shantanu Karkare & Anthony Maxwell
Received: 17 June 2011 /Revised: 8 August 2011 /Accepted: 18 August 2011 /Published online: 9 September 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract DNA gyrase is a type II topoisomerase that can
introduce negative supercoils into DNA at the expense of
ATP hydrolysis. It is essential in all bacteria but absent from
higher eukaryotes, making it an attractive target for
antibacterials. The fluoroquinolones are examples of very
successful gyrase-targeted drugs, but the rise in bacterial
resistance to these agents means that we not only need to
seek new compounds, but also new modes of inhibition of
this enzyme. We review known gyrase-specific drugs and
toxins and assess the prospects for developing new
antibacterials targeted to this enzyme.
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Introduction
DNA topoisomerases are enzymes that catalyse changes in
the topology of DNA (Bates and Maxwell 2005; Wang
2009), i.e., they can interconvert relaxed and supercoiled
forms and introduce and remove catenanes and knots
(Schoeffler and Berger 2008; Dong and Berger 2008).
These enzymes are found in all cell types and are essential
to survival. Due to their essential nature and to their
mechanisms of action (see below), topoisomerases have
become key drug targets both for antibacterial and anti-
cancer chemotherapy (Pommier et al. 2010; Tse-Dinh 2007;
Bradbury and Pucci 2008).
DNA topoisomerases can be divided into two types, I
and II, depending on whether they catalyse reactions
involving the transient breakage of one (type I) or both
(type II) strands of DNA (Liu et al. 1980). All top-
oisomerases (topos) can relax supercoiled DNA, but only
DNA gyrase (a type II enzyme) can also introduce negative
supercoils in a reaction that requires the hydrolysis of ATP
(Nollmann et al. 2007; Bates and Maxwell 2007). Whereas
eukaryotic type II topos, such as human or yeast topo II, are
large single-subunit enzymes (∼170 kDa) that are active as
homodimers, prokaryotic enzymes, such as gyrase and its
close relative topo IV, are composed of two subunits: A and
B in the case of gyrase, which associate to form an A2B2
complex in the active enzyme (Champoux 2001). The best-
studied gyrase is that from Escherichia coli, which has A
and B subunits (GyrA and GyrB) of molecular weights 97
and 90 kDa, respectively (Reece and Maxwell 1991).
Broadly speaking, the A subunit is involved with inter-
actions with DNA, it contains the active-site tyrosine
responsible for DNA cleavage, and the B subunit contains
the ATPase active site. There is currently no high-resolution
structure for the gyrase holoenzyme (A2B2), but several X-
ray crystal structures exist for individual domains from
various bacterial species (Corbett et al. 2004; Morais Cabral
et al. 1997; Wigley et al. 1991; Edwards et al. 2009;F ue t
al. 2009; Piton et al. 2010; Tretter et al. 2010; Hsieh et al.
2010), a fusion of a GyrB with a GyrA domain, with and
without DNA (Bax et al. 2010; Schoeffler et al. 2010), and
low resolution small-angle X-ray scattering structures of the
GyrA and GyrB proteins (Costenaro et al. 2005; Costenaro
et al. 2007), and intact gyrase (Baker et al. 2011). Taken
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the overall organisation of the A2B2 complex and how it
introduces supercoils into DNA.
Mechanism of DNA supercoiling by DNA gyrase
The usefulness of gyrase as a target of antibacterial agents
stems from its mechanism of supercoiling (Schoeffler and
Berger 2008; Nollmann et al. 2007). The details of this
mechanism are still under investigation, but a model,
generically known as the “two-gate mechanism” (Roca
and Wang 1992, 1994), is strongly supported by biochem-
ical and structural data. DNA gyrase possesses three
interfaces that can be in an open or closed conformation
(Fig. 1): the N-terminal domain of GyrB (referred to as the
N-gate), the GyrA–GyrB–DNA interface, where the DNA
is cleaved (referred to as the DNA gate), and the C-terminal
area of coiled coils, which forms the C or exit gate (Fig. 1).
The supercoiling reaction is thought to progress as follows:
the DNA G (or gate) segment associates with the enzyme,
at the interface of the N terminus of the GyrA dimer and the
TOPRIM domain of GyrB (Bax et al. 2010; Morais Cabral
et al. 1997), and DNA is wrapped around the enzyme in a
right-handed supercoil of ∼130 base pairs (Orphanides and
Maxwell 1994). Wrapping of DNA on the gyrase C-
terminal domains facilitates a second segment (the trans-
ported or T segment) belonging to the same DNA molecule
to reach the N gate, which is positioned over the G segment
in preparation for strand passage (Heddle et al. 2004).
Binding of ATP results in closure of the N gate and trapping
of the T segment (Brino et al. 2000; Wigley et al. 1991).
The enzyme cleaves the G segment forming DNA–
phosphotyrosyl bonds 4 bp apart, thus creating a double-
strand break and resulting in the covalent attachment of
GyrA to the DNA. The T segment is passed through the
open DNA gate and the broken G segment, and ultimately
through the exit gate (Fig. 1). The passage of the T segment
through the G segment (strand passage) is driven by the
binding and hydrolysis of ATP. The hydrolysis of ATP and
release of ADP opens the N gate and resets the enzyme for
the next supercoiling cycle. One gyrase supercoiling cycle
introduces two negative supercoils into the DNA molecule
at the expense of 2 ATPs (Bates and Maxwell 2007). In the
absence of ATP, gyrase can catalyse relaxation of negatively
supercoiled DNA, essentially by the reverse mechanism
(Gellert et al. 1977; Williams and Maxwell 1999b).
The gyrase supercoiling reaction is a complex process
that is incompletely understood. However, through a
combination of structural and mechanistic experiments,
we currently have an overall understanding of this process
(Fig. 1). What is clear is that the gyrase supercoiling cycle
gives ample opportunity for disruption by inhibitors, which
can, for example, interfere with DNA binding, DNA
cleavage, strand passage and ATP hydrolysis. The exploit-
ability of this reaction has, in part, made gyrase a very
attractive target for antibacterial agents. In the following
sections, we will summarise what is currently known about
such agents and speculate on the possibilities for the
development of new therapeutic agents that target gyrase.
Catalytic inhibitors of gyrase vs. gyrase poisons
Two main mechanisms are responsible for the antibacterial
activity of drugs targeting gyrase. The first is the inhibition
of the enzymatic activity of gyrase, and the second involves
stabilisation of the covalent enzyme–DNA complex, or
gyrase poisoning. Novobiocin, a compound that inhibits the
ATPase activity of gyrase, is an example of a catalytic
inhibitor (Fig. 3), and ciprofloxacin (Fig. 2) is an example
of a cleavage-complex stabilising agent. Figure 1 gives
examples of the proposed points of action of various
inhibitors on the gyrase supercoiling reaction: simocycli-
none prevents DNA binding, ciprofloxacin interrupts DNA
cleavage-religation and stabilises the cleavage complex,
and novobiocin inhibits the ATPase activity. It is cleavage-
complex stabilisation that has been found to be the most
effective mode of action of inhibitors of gyrase and other
topoisomerases (Anderson and Osheroff 2001; Drlica et al.
2009). This is because relatively low occupancy of an
inhibitor bound to its target can lead to sufficient protein-
stabilised breaks in DNA to initiate a cascade of events that
ultimately result in cell death (Drlica et al. 2009; Kohanski
et al. 2010; Kohanski et al. 2007). In bacteria, this is
thought to involve chromosome fragmentation, the induc-
tion of the SOS response, and the production of reactive
oxygen species (Drlica et al. 2009; Kohanski et al. 2010;
Kohanski et al. 2007). This mode of action is employed by
the fluoroquinolones, such as ciprofloxacin, and is respon-
sible for their success. Although ‘poisoning’seems to be the
ideal mode of action for compounds targeted to gyrase, the
possibility of developing catalytic inhibitors as effective
drugs should not be ruled out.
Quinolones
Quinolones are by far the most successful antibacterials
targeted to DNA gyrase. The compounds originated from
nalidixic acid, a naphthyridone discovered by accident as a
by-product during the synthesis of chloroquine (Fig. 2;
Lesher et al. 1962). The first-generation quinolones,
nalidixic acid and oxolinic acid have relatively weak
antimicrobial activity, but the synthesis of the fluoroquino-
lones and their improvement over several generations, e.g.,
480 Appl Microbiol Biotechnol (2011) 92:479–497norfloxacin and ciprofloxacin (second generation), levo-
floxacin (third gen.) and moxifloxacin and gemifloxacin
(fourth gen.), has led to a range of potent antibacterial
compounds that have enjoyed enormous clinical and
commercial success (Emmerson and Jones 2003; King et
al. 2000; Oliphant and Green 2002).
Although gyrase is the target for quinolones in Gram-
negative bacteria, topo IV can be the preferred target in
some Gram-positive organisms (Hooper 2003), this being
dependent on the particular organism and the quinolone
(Ferrero et al. 1994; Pan and Fisher 1997). The indicator of
primary target is the site of point mutations that confer
quinolone resistance. This tends to be largely restricted to
discrete regions of gyrA and gyrB (or parC and ParE, the
equivalent topo IV genes) that are termed the quinolone-
resistance-determining regions or QRDRs (Yoshida et al.
1991; Yoshida et al. 1990). Amino acids in these regions
have subsequently been found to be important in the
interaction with the drugs from X-ray crystal structures
(see below).
In vivo, quinolones can have both bacteriostatic and
bactericidal actions (Drlica et al. 2009; Drlica and Hooper
2003). The bacteriostatic effects are largely a consequence of
replication-fork arrest by quinolone–gyrase (or quinolone–
topo IV) complexes on DNA. Such events do not necessarily
lead to DNA breakage and cell death. The lethal action of
quinolones is proposed to involve two pathways, one that is
dependent upon protein synthesis and one that can occur in its
absence, for example, in the presence of the inhibitor
chloramphenicol (Drlica et al. 2009; Drlica and Hooper
2003). First-generation compounds, such as nalidixic acid,
are not lethal when protein synthesis is inhibited, whereas
Fig. 1 Gyrase mechanism
(adapted from Costenaro et al.
2007). 1 Free states of the
proteins and DNA. 2 Wrapping
of the DNA around the enzyme
presents the T segment over the
G segment. 3 Upon ATP bind-
ing, GyrB dimerises, captures
the T segment, and the G
segment is transiently cleaved.
4 Hydrolysis of one ATP allows
GyrB to rotate, the GyrA open-
ing to widen and the transport
of the T segment through the
cleaved G segment. 5 Religation
of the G segment results in the
introduction of two negative
supercoils into DNA; release of
the T segment and hydrolysis
of the second ATP resets the
enzyme. Stars indicate the posi-
tions of the active-site residues
for DNA cleavage, and the
circle indicates the ATP-binding
pocket. Colour code of the
domains: GyrA59 (N-terminal
domain; NTD), orange; GyrA-
CTD, cyan; GyrB43 (NTD),
blue; Toprim, red; Tail, green;
G segment, black; T segment,
purple. The approximate points
of action of simocyclinone,
novobiocin and ciprofloxacin
are shown. N, D and E indicate
the locations of the N gate,
DNA gate and exit gate,
respectively (reprinted with
permission from Elsevier;
Costenaro et al. 2007)
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kill cells irrespective of protein synthesis. A consequence of
quinolone-stabilised gyrase (or topo IV) complexes on DNA
is chromosome fragmentation and ultimately cell death via a
pathway that may involve active oxygen species (Dwyer et
al. 2007; Kohanski et al. 2010;K o h a n s k ie ta l .2007).
Quinolones inhibit the DNA supercoiling and relaxation
reactions of gyrase and can stabilise a covalent complex in
Fig. 2 Quinolones. a Examples
of fluoroquinolones and their
precursor nalidixic acid. b
Structure of the topo IV–fluoro-
quinolone complex (Laponogov
et al. 2009). Upper: front view
of the topo IV ParC55 and
ParE30 proteins complexed with
the G segment DNA and moxi-
floxacin, shown in cartoon rep-
resentation. DNA is green, the
TOPRIM domain (ParE30) is in
yellow and the ParC55 is blue.
The moxifloxacin molecules are
shown in red. Lower: close up of
the quinolone–topo IV cleavage
complex in cartoon representa-
tion. The active site tyrosines
(Tyr118) are in orange and the
residues responsible for drug
resistance upon mutation are
shown in yellow (b is repro-
duced with permission from
Nature Publishing Group;
Laponogov et al. 2009)
482 Appl Microbiol Biotechnol (2011) 92:479–497which the GyrA protein is covalently attached to the 5′ ends
of the broken DNA (Gellert et al. 1977; Sugino et al. 1977).
From biochemical experiments, it was possible to deduce
that quinolone action involved interactions with DNA,
likely via intercalation, and interactions with the enzyme,
likely to both subunits (Heddle and Maxwell 2002; Heddle
et al. 2000). However, the details of these interactions have
only been revealed very recently with the publications of X-
ray structures of fragments of gyrase (and topo IV)
complexed with DNA and quinolone drugs (Bax et al.
2010; Laponogov et al. 2010; Laponogov et al. 2009;
Wohlkonig et al. 2010). These structures (e.g., Fig. 2b)
show in detail how the drugs interact with the enzyme and
DNA, and in so doing, disrupt the DNA cleavage-religation
process. Although there are differences in detail concerning
the specific interactions, which may be accounted for by the
different sources of the enzyme, the different drugs
employed, and/or the resolution of the structures, the
overall mode of interaction is very similar and now gives
us a very good idea as to how quinolones interact with
gyrase (and topo IV) at the molecular level.
Success in crystallising gyrase–DNA–quinolone com-
plexes has come from the construction of fusion proteins
involving the C-terminal domain of GyrB (or ParE in the
case of topo IV) with the N-terminal domain of GyrA (or
ParC for topo IV). This generates a protein that retains
catalytic activity, i.e., the ability to carry our DNA
breakage-reunion and that emulates the structure of eukary-
otic topo II (Berger et al. 1996). The structures solved (Bax
et al. 2010; Laponogov et al. 2010; Laponogov et al. 2009;
Wohlkonig et al. 2010) all show the DNA gate in the closed
conformation, implying that opening of this gate is not a
prerequisite for quinolone binding and DNA cleavage,
consistent with earlier biochemical studies (Williams and
Maxwell 1999a). The aromatic rings of the quinolone are
found to be stacked against the DNA bases at the site of
DNA cleavage, i.e., between the −1 and +1 base pairs,
which straddle the site of DNA cleavage (Fig. 2b). It is easy
to imagine how such an interaction could lead to misalign-
ment of the DNA either side of the break and subsequent
difficulty in religating the broken DNA. The exact
interactions of the drugs with the proteins are not entirely
clear as there are differences between the published
structures. However, it is likely that these involve the Ser
and Asp (or Glu) residues in GyrA that are commonly
mutated in quinolone-resistant bacteria (e.g., Ser
83 and
Asp
87 in E. coli)a n daM g
2+ ion, consistent with
biochemical studies (Sissi and Palumbo 2009).
These structures not only rationalise the activity and
potency of current quinolones but will enable the design of
new agents, whether quinolone or non-quinolone, that may
overcome the problems of resistance encountered with
existing agents.
Aminocoumarins
Aminocoumarins, also referred to as coumarins, are com-
pounds containing a 3-amino-4,7-dihydroxycoumarin ring
(Fig. 3). The aminocoumarins, novobiocin, clorobiocin and
coumermycin A1, are natural products isolated from Strep-
tomyces species; there are now also many derivatives made
by genetic manipulation, metabolic engineering and muta-
synthesis (Heide 2009b), and by chemical synthesis (Oblak
et al. 2007). Simocyclinones also contain the aminocoumarin
moiety but in addition contain an angucyclinone polyketide
group (Schimana et al. 2000). Both classical aminocoumar-
ins and simocyclinones are antibiotics that target DNA
gyrase, but they do so in entirely different ways.
Classical aminocoumarins
In many ways, aminocoumarins are regarded as the
‘Cinderellas’ of the gyrase inhibitors, particularly in
comparison with fluoroquinolones. Although they bind
tightly to gyrase, they have not enjoyed significant clinical
success. The classical aminocoumarins share common
structural features: a 3-amino-4, 7-dihydroxycoumarin
structure, an L-noviosyl sugar and an aromatic acyl
component attached to the amino group of the amino-
coumarin moiety (Fig. 3; Heide 2009a). The difference
between clorobiocin and novobiocin is the substitution of
the methyl group at the 8′ position of the coumarin ring
with a chlorine atom, and a 5-methyl-pyrrole-2-carboxyl
group substitutes the carbamoyl group at the 3′ position of
the noviose. Coumermycin A1 has coumarin rings attached
to either side of a pyrrole group; a substituted sugar is
attached to each of the coumarin rings, and a pyrrole group
is attached to each noviose sugar.
Known since the 1950s for their inhibitory properties on
nucleic acid synthesis in bacteria, it was found later, with
the discovery of DNA gyrase, that aminocoumarins inhibit
gyrase-catalysed supercoiling of DNA (Gellert et al. 1976).
It was further shown that they inhibit the gyrase ATPase
reaction by competing with ATP for binding to GyrB
(Mizuuchi et al. 1978; Sugino and Cozzarelli 1980; Sugino
et al. 1978). Their binding site lies in the 24-kDa amino-
terminal sub-domain of GyrB (Gilbert and Maxwell 1994),
a domain that does not bind ATP by itself; nonetheless, they
overlap the ATP-binding site, thus preventing ATP binding
(Lewis et al. 1996a).
The interactions of aminocoumarins with DNA gyrase are
extremely well characterised; several high-resolution crystal
structures exist (Lewis et al. 1996b; Maxwell and Lawson
2003). These include the 24-kDa N-terminal sub-domain of
E. coli GyrB complexed with novobiocin (Holdgate et al.
1997; Lewis et al. 1996a) and clorobiocin (Tsai et al. 1997;
Lafitte et al. 2002), and Thermus thermophilus GyrB43
Appl Microbiol Biotechnol (2011) 92:479–497 483complexed with novobiocin (Lamour et al. 2002). These
crystal structures clearly show an overlap in the binding of
ATP and the aminocoumarin, specifically the binding site of
the noviose sugar and the adenine ring of ATP overlap
(Fig. 3b). This illustrates how aminocoumarins can be
competitive inhibitors of ATP hydrolysis by gyrase despite
having limited structural resemblance to ATP.
Because of the overlap between the ATP- and
aminocoumarin-binding sites in GyrB, resistance to amino-
coumarins that maps to gyrB is limited to amino acids that
do not significantly affect the supercoiling activity of
gyrase, as this enzyme is essential to survival. Naturally
occurring gyrB mutations to aminocoumarin resistance
occurpredominantlyatArg
136 (E. coli numbering) (Contreras
and Maxwell 1992; del Castillo et al. 1991;H o l m e sa n d
Dyall-Smith 1991; Samuels et al. 1994), a residue that
contacts the aminocoumarin ring of the drugs (Lewis et al.
1996a). A mutation to Gly
164 (to Val) also confers resistance
Fig. 3 Aminocoumarins. a
Classical aminocoumarins. b
Upper: structure of the N-
terminal domain of GyrB
(GyrB43) complexed with an
ATP analogue (Wigley et al.
1991); the protein is in cartoon
representation with the two
monomers in shades of green
and shades of yellow; the nucle-
otide is in space-filling repre-
sentation (reproduced with
permission (Maxwell and
Lawson 2003)). Lower: structure
of the N-terminal sub-domain of
GyrB (GyrB24) complexed with
novobiocin (blue) showing the
overlap with bound ATP (Lewis et
al. 1996a). c Simocyclinone D8.
d Upper: structure of the complex
between simocyclinone D8 and the
N-terminal domain of GyrA
(GyrA59) (Edwards et al. 2009).
The protein dimer is shown in blue
in cartoon representation and the
drug in yellow in stick representa-
tion (reprinted with permission
from AAAS; Edwards et al. 2009)
Lower: detail of the
simocyclinone-binding pockets in
GyrA showing two alternative
modes of interaction (Edwards et
al. 2009; Edwards et al. 2011). The
blue subunit has the two
simocyclinone pockets occupied
by two different simocyclinone
molecules; the brown subunit has a
single simocyclinone molecule
bridging both pockets (reprinted
with permission from the
American Chemical Society;
Edwards et al. 2011)
484 Appl Microbiol Biotechnol (2011) 92:479–497and also a temperature-sensitive phenotype (Contreras and
Maxwell 1992). GyrB proteins bearing these mutations show
loss of enzymic activity due to impaired ATPase activity
(Contreras and Maxwell 1992; Gross et al. 2003). It is feasible
to make site-directed mutations in GyrB at residues that make
contact with the bound aminocoumarin. For example, muta-
tions at Asp
73 (to Asn) and Asn
46 ( t oA s pa n dL e u )i nE. coli
GyrB have been made (Kampranis et al. 1999a), and, although
the mutant GyrB proteins show reduced drug binding, they
were catalytically inactive due to their failure to bind ATP. In
other work, E. coli GyrB mutations at Asp
73 (to Glu), Gly
77 (to
Ala and Ser), Ile
78 (to Ala and Leu), and Thr
165 (to Ala and
Val) were found to confer resistance to novobiocin but with a
concomitant loss in enzyme activity (Gross et al. 2003). Taken
together, it appears that mutations conferring resistance to
aminocoumarins tend to inactivate the enzyme due to their
proximity to the ATPase active site. This feature is attractive
when considering clinical antibacterials targeted to this site.
Simocyclinones
Simocyclinones are hybrid antibiotics containing both amino-
coumarin and polyketide elements (Fig. 3c); there are a
number of simocyclinone variants produced by Streptomyces
antibioticus Tü 6040 that are mostly intermediates of
simocyclinone D8 (SD8) (Theobald et al. 2000; Trefzer et
al. 2002). SD8 has only modest antibacterial properties, it is
most potent against Gram-positive organisms, such as
Streptomyces viridochromogenes Tü 57, and largely ineffec-
tive against Gram-negative bacteria (Richter et al. 2010;
Schimana et al. 2000), although it appears to have higher
potency in clinical settings (Richter et al. 2010). Its target is
bacterial gyrase (Edwards et al. 2009; Flatman et al. 2005)
showing potency against both the E. coli and Staphylococcus
aureus enzymes (Oppegard et al. 2009) but not against their
topo IV counterparts. SD8 also has cytotoxic activity against
human cells (Sadiq et al. 2009; Schimana et al. 2000), where
its target appears to be human topoisomerase II (Flatman et
al. 2006; Sadiq et al. 2009). The biosynthetic gene cluster of
SD8 shares genes that are related to those found in the gene
clusters of the classical aminocoumarins (Galm et al. 2002;
Trefzer et al. 2002). Despite its relatedness to the classical
aminocoumarins, SD8 does not target the ATPase binding
site of GyrB, located within the N-terminal domain, but
binds to the N-terminal domain of GyrA at the region that
also binds DNA (Edwards et al. 2009; Flatman et al. 2006);
evidence for a second binding site in the C-terminal domain
of GyrB has also been found (Sissi et al. 2010). The action
of SD8 on gyrase is to prevent DNA binding. This occurs via
the interaction of the aminocoumarin and angucylic polyke-
tide with two separate binding pockets in the N-terminal
domain of GyrA (Edwards et al. 2009), i.e., SD8 is a ‘two-
headed’ antibiotic. The crystal structure shows that four SD8
molecules stabilise a tetramer of GyrA, with one SD8
bridging two GyrA monomers (Fig. 3d). An alternative
model in which a single SD8 bridges the two binding sites in
the same GyrA subunit is supported by mass spectrometry
data (Edwards et al. 2009; Edwards et al. 2011). This novel
mechanism of action could be potentially exploited in the
development of new antibacterial agents.
Perspectives on coumarins
Coumarins are potent inhibitors of gyrase in vitro, but their
poor activity against Gram-negative bacteria, mammalian
cytotoxicity and poor solubility prevent them from being
clinically successful drugs. However, their study has shed
light on mechanistic aspects of gyrase, and their mode of
action could be emulated by other compounds having more
attractive properties. Continued investigation of the
coumarins could promote the development of new
generations of non-quinolone, gyrase-targeted antibacte-
Fig. 3 (continued)
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compounds, the classical aminocoumarins and the
simocyclinones, which are evolutionarily related, target
the same enzyme (gyrase) but bind at different subunits.
A further twist to this story is the proposed existence of
a simocyclinone-binding site in GyrB (Sissi et al. 2010),
the significance of which is presently not clear.
Other small molecule inhibitors
From the foregoing discussion, it is clear that it is
possible to develop small molecule inhibitors of bacterial
gyrase that can be utilised in a clinical context. In terms
of the complexity of the gyrase supercoiling reaction
(Fig. 1), it is likely that we have probably really only just
scratched the surface of the potential for targeting this
enzyme. By analogy, there are a wide range of inhibitors
of topo II that target the enzyme at various stages of its
catalytic cycle (Larsen et al. 2003). Over the years, and
particularly in the recent past, a host of small molecule
inhibitors of gyrase have been reported in the literature.
None of these have yet made it into clinical practice, but
this is more likely to be a consequence of commercial
rather than scientific considerations. Below, we review
some of these compounds; the discussion is necessarily
Fig. 4 Other small molecule gyrase inhibitors
486 Appl Microbiol Biotechnol (2011) 92:479–497incomplete as the literature is peppered with possible
agents active against gyrase.
Cyclothialidines
Cyclothialidines are cyclic peptides with antibacterial
activity produced by streptomycetes (Goetschi et al.
1993). The compounds generally have poor antimicrobial
activity only showing significant effects on eubacteria
(Nakada et al. 1993; Goetschi et al. 1993). A number of
analogues, some with improved activities, have been
synthesised (Angehrn et al. 2004; Goetschi et al. 1993).
Cyclothialidine (Ro 09-1437; Fig. 4) is produced by
Streptomyces filipinensis and has been shown to target
DNA gyrase specifically by binding to the B subunit and
inhibiting the ATPase activity (Goetschi et al. 1993; Nakada
et al. 1994; Oram et al. 1996). A crystal structure of the
related compound GR122222X shows that, like novobiocin,
the compound binds to the GyrB N-terminal domain at a site
that overlaps with the ATP-binding site (Lewis et al. 1996a).
Like the classical aminocoumarins, cyclothialidines are
competitive inhibitors of the gyrase ATPase reaction by
virtue of this overlap (Nakada et al. 1995;O r a me ta l .1996).
Mutants conferring resistance to cyclothialidines have been
generated in S. aureus and found to map to the ATP-binding
region of GyrB as expected (Stieger et al. 1996).
Cinodine
Cinodine is a compound produced by Nocardia species that
belongs to the glycocinnamoylspermidine antibiotic class
(Fig. 4)( M a r t i ne ta l .1978; Tresner et al. 1978); three
different forms, β, γ1 and γ2 have been identified. It has been
shown to inhibit bacterial DNA synthesis (Greenstein et al.
1981) and DNA supercoiling by Micrococcus luteus gyrase in
vitro (Osburne et al. 1990). Cinodine-resistant mutants have
been found to map to the gyrA gene (Osburne 1995),
supporting the idea that gyrase is the target of cinodine in vivo.
Clerocidin
The diterpenoid clerocidin (Fig. 4) was isolated from the
fungus Oidiodendron truncatum, it is known as a cytotoxic
and antibacterial agent (Andersen and Rasmussen 1984)
that stimulates in vitro DNA cleavage, mediated by
eukaryotic DNA topo II (Kawada et al. 1991) and gyrase
(McCullough et al. 1993). Clerocidin has been shown to
promote in vitro cleavage by Streptococcus pneumoniae
gyrase and topo IV (Pan et al. 2008; Richter et al. 2006).
Clerocidin differs from other topoisomerase poisons in that
it creates a break at the guanine immediately preceding the
topoisomerase DNA-cleavage site. This break cannot be
resealed by heating or salt treatment (Pan et al. 2008; Gatto
et al. 2001). In the absence of topoisomerases, clerocidin is
able to nick negatively supercoiled DNA and form adducts
with the guanines in short unpaired oligos (Gatto et al.
2001). This reaction was shown to involve the attack by the
clerocidin epoxide group of the guanine nitrogen at N
7,
leading to strand scission at the modified site (Gatto et al.
2001; Richter et al. 2003). Concerning the clerocidin
structure, additional to the reactive epoxide function, the
carbonyl group and oxirane ring have been shown to be
essential for its activity (Richter et al. 2003). The
replacement of the diterpenoid moiety by a naphthalene
ring system was reported to have no effect on the reaction
with the bases in the absence of a topoisomerase (Richter et
al. 2003); however, it causes a loss of the clerocidin
cleavage activity in presence of S. pneumoniae topo IV
(Richter et al. 2006). With S. pneumoniae topo IV,
clerocidin was still able to create strand breaks with
quinolone-resistant ParC(S79F), but not with the cleavage-
deficient ParC(Y118F) active-site mutant (Richter et al.
2006). Evidence suggests that during the formation of the
topoisomerase–DNA cleavage complex, the DNA adopts a
conformation favourable for the reaction of clerocidin with
a guanidine occupying the −1 and/or +5 position of the
cleavage site; alternatively, reversible cleavage will be
favoured if a cytosine is present at one of these positions
(Richter et al. 2006). Clerocidin possesses an unusual mode
of action, but the compound itself is too toxic to be used as
a drug; less toxic molecules able to mimic clerocidin
activity would be of major interest.
Albicidin
Xanthomonas albilineans, the sugarcane scald pathogen,
produces a family of antibiotics and phytotoxins known
as albicidins. The major component of this mixture,
albicidin, is bactericidal to E. coli and inhibits DNA
synthesis (Birch and Patil 1985). Relatively little is
known about the toxin, although it is thought to contain
38 C-atoms and several aromatic rings, and to be the
product of a least two separate gene clusters in X.
albilineans ( R o t te ta l .1996). Albicidin has been shown
to be an inhibitor of E. coli and Arabidopsis thaliana
DNA gyrase and to stabilise the cleavage complex in the
presence of ATP (Hashimi et al. 2007). Although its
precise mode of action is not yet clear, it appears to act in
a manner distinct from other known gyrase inhibitors. X.
albilineans gyrase is resistant to albicidin and a hybrid
enzyme comprising the X. albilineans gyrase A subunit
and the E. coli gyrase B subunit is active and also
resistant, suggesting that GyrA is the target of albicidin
(Hashimi et al. 2008). Currently, the albicidin structure is
not known, but its apparently unique mode of action and
the fact that it stabilises the cleavage complex make it an
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ment of new antibacterial agents.
New synthetic small molecules
There are a whole host of small molecules, sometimes
referred to by the catch-all term of new bacterial top-
oisomerase inhibitors (NBTIs), which are antibacterial
compounds not belonging to the quinolone chemical family
but acting in a similar manner and not affected by
quinolone-resistance mutations (Widdowson and Hennessy
2010). Researchers from GlaxoSmithKline have identified a
potent DNA gyrase inhibitor, GSK299423 (Fig. 4) and
solved its structure bound to S. aureus gyrase and DNA
(Bax et al. 2010). The compound binds to the enzyme–
DNA complex in the same region as the quinolone drug
ciprofloxacin but at a distinct site. Unlike quinolones,
GSK299423 does not stabilise the gyrase cleavage complex
and induce double-strand breaks, but appears to induce
single-stranded breaks in DNA (Bax et al. 2010), i.e., it
appears to have a novel mode of action.
Other compounds that potentially fall into the NBTI
class (Fig. 4) are a series of tetrahydroindazoles discovered
by researchers at Johnson and Johnson (Gomez et al. 2007;
Wiener et al. 2007), quinazoline-2,4-diones PD0305970
and PD0326448, from Pfizer (Huband et al. 2007), QPT-1,
also from Pfizer (Miller et al. 2008), and the quinoline-
based drug NXL-101 from Novexel (Black et al. 2008). It is
not yet clear whether these compounds will enjoy the level
of clinical success enjoyed by the fluoroquinolones.
Proteinaceous inhibitors
Aside from small molecule inhibitors of gyrase, there are a
number of larger molecular weight protein-based inhibitors.
These have distinct mechanisms of action that could, in
principle, be emulated by small molecules to generate novel
antimicrobial agents.
Microcin B17
Microcin B17 (MccB17; Fig. 5) is a 3.1-kDa glycine-rich
peptide produced by enterobacteria carrying the pMccB17
plasmid (Davagnino et al. 1986). Its 3-D structure is not yet
known, but a model has been suggested (Fig. 5b; Parks et
al. 2007). The peptide is post-translationally modified to
convert serine- and cysteine- residues into oxazole, thia-
zole, and oxazole–thiazole fused rings (Yorgey et al. 1994).
MccB17 is active against many enterobacteria (Asensio et
al. 1976) and has been shown to inhibit DNA replication,
triggering the SOS response, and inducing DNA degrada-
tion and cell death (Herrero and Moreno 1986). Genetic and
biochemical approaches have shown that the effect of
MccB17 is linked to its ability to induce E. coli gyrase-
mediated double-strand cleavage of DNA (Vizán et al.
1991). MccB17 is a relatively weak inhibitor of gyrase
compared to quinolones and works via a different mecha-
nism. The toxin does not completely inhibit the super-
coiling and relaxation reaction of gyrase but merely slows
them down by about threefold (Pierrat and Maxwell 2003).
The effect of MccB17 on the DNA cleavage reaction in
vitro is topology dependent: under supercoiling conditions,
with relaxed DNA as substrate, MccB17 can only weakly
stabilise the cleavage complex in the absence of ATP, but in
its presence, cleavage is more efficiently stabilised. Under
relaxation conditions, with a negatively supercoiled DNA
as substrate, MccB17 can more efficiently stabilise the
cleavage complex in the absence of ATP (Pierrat and
Maxwell 2003). It has been shown that MccB17 does not
require the DNA-wrapping (C-terminal) domain of GyrA or
the ATPase (N-terminal) domain of GyrB (Pierrat and
Maxwell 2005). This evidence, added to the fact that the
only known MccB17-resistant mutation is at amino acid
751 of GyrB (W751R; Vizán et al. 1991), has led to the
idea that the action of the toxin involves binding to the C-
terminal domain of GyrB, preventing strand passage by
trapping a transient enzyme intermediate (Pierrat and
Maxwell 2005). Some quinolone-resistance mutations,
GyrB (K447E) and GyrA (S83W), provide limited resis-
tance to MccB17, but the CcdB-resistant mutant GyrA
(R462C) is sensitive to MccB17 (Heddle et al. 2001); the
significance of these data are presently not clear. The
MccB17-producing strain contains three genes: mcbEFG
that confers immunity to the host (Garrido et al. 1988);
mcbEF that encodes a pump; and mcbG that encodes an
immunity protein (San Millan et al. 1985)t h a ti sa
pentapeptide repeat protein (see below). Interestingly, it
has been shown that mcbEFG can confer resistance to
fluoroquinolones (Lomovskaya et al. 1996).
Taken together, it seems that MccB17 binds to gyrase at
a site that involves the C-terminal domain of GyrB and that
this complex slows down DNA strand passage and
stabilises the cleavage complex. It is likely that MccB17
recognises a conformation of the enzyme that is only
revealed during the strand-passage process, the toxin
perhaps binding to transiently exposed hydrophobic regions
of the enzyme (Parks et al. 2007). This makes MccB17 an
attractive prospect in relation to the development of novel
antibacterials, as it stabilises the gyrase–DNA cleavage
complex by a mechanism that is probably distinct from the
quinolones. Unfortunately, due its unattractive physico-
chemical properties, it is inappropriate to be used as a drug;
however, it is an attractive resource for designing novel
drugs based on its particular heterocyclic structure and
mechanism of action. The possibility of efficiently making
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Videnov et al. 1996) raises this as a serious possibility.
CcdB
CcdB (Fig. 6) is a 11.7-kDa protein that is produced as a
part of a two-component toxin–antitoxin system involved in
the maintenance of the copy number of the F plasmid (Miki
et al. 1984; Miki et al. 1992). CcdB is active as a dimer and
is inactivated by CcdA (Loris et al. 1999; Madl et al. 2006);
its intracellular target is DNA gyrase (Bernard and
Couturier 1992; Bernard et al. 1993). CcdB kills bacteria
by a mechanism similar to quinolones insofar as it involves
stabilisation of the cleavage complex, although evidence
shows that the interaction between CcdB and gyrase is
significantly different. The mutation of Arg
462 to Cys in
GyrA, which confers gyrase resistance to CcdB (Bernard
and Couturier 1992), is located in the central cavity of
Fig. 5 Microcin B17. a Primary structure. b Proposed 3-D structure (adapted from (Parks et al. 2007) with permission from Elsevier). Letters A–F
indicate the heterocycles, and key amino acids are numbered
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DNA come together (2) to form the holoenzyme with the G segment
binding across the DNA gate (3). The DNA is wrapped around GyrA
presenting the T segment over the G segment (4). Upon ATP binding,
the GyrB monomers dimerise (5), the G segment is cleaved and the
DNA gate opens. Either (6a) ‘top-down’ passage of the T segment
occurs upon hydrolysis of a single ATP or (6b) CcdB accesses its
binding site to stabilise the cleavage complex. A futile ATP hydrolysis/
ATP binding cycle can occur (Kampranis et al. 1999b). Several cycles
of (5)t o( 6a) transition may occur prior to CcdB binding. In the
normal cycle, the DNA gate closes, the G segment is religated and the
T segment passes out through the bottom gate, with hydrolysis of the
second ATP resetting the enzyme (7) (reproduced from (Smith and
Maxwell 2006) with permission from Oxford University Press.) b
Complex of CcdB and GyrA14 and models: (a) Gyr-A14: CcdB
complex viewed along its twofold axis. The two CcdB monomers are
drawn in orange and red and the two GyrA14 monomers in two shades
of blue.( b)S a m ea s( a), but rotated 90°. (c) Model of closed GyrA59
(blue)w i t hC c d B( green) docked onto it by superposition of the
GyrA14:CcdB complex on the crystal structure of GyrA59. Residues
Arg462 of both monomers of GyrA59 are highlighted. Strong steric
overlaps (red) with the CAP domains are observed. (d) Model of the
GyrA59:CcdB complex with GyrA59 in its open conformation. The
open conformation of GyrA59 was modelled according to the
corresponding yeast topoisomerase II structure (PDB entry 1BGW). In
this model, there is no steric overlap between CcdB and GyrA59
(reproduced from (Dao-Thi et al. 2005) with permission from Elsevier)
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(Morais Cabral et al. 1997); no cross-resistance between
CcdB and quinolones has been observed (Bernard et al.
1993; Critchlow et al. 1997). Biochemical evidence shows
that there are significant differences in the modes of action
of quinolones and CcdB. CcdB-induced cleavage of DNA
by gyrase requires nucleotides (ATP for linear or relaxed
DNA and a non-hydrolysable nucleotide for negatively
supercoiled DNA) and DNA templates of at least
1 6 0b p( C r i t c h l o we ta l .1997), whereas quinolone-
induced cleavage does not generally require ATP, and
DNA substrates of ∼20 bp can be cleaved (Cove et al.
1997; Gmünder et al. 1997). In contrast to quinolones,
CcdB is unable to mediate DNA cleavage with gyrases
containing just the N-terminal domain of GyrA (GyrA64
associated with GyrB; Critchlow et al. 1997).
A crystal structure of CcdB with an N-terminal fragment
of GyrA (GyrA14) (Dao-Thi et al. 2005) suggests that the
toxin binds to the GyrA dimer in the cavity between the
two subunits, confirming the role of Arg
462 in CcdB
binding to GyrA (Fig. 6b). This residue makes key contacts
with residues at the C-terminal end of CcdB. Modelling
suggests that the CcdB dimer can be accommodated in the
cavity within the dimer of the GyrA N-terminal domain, but
only when the enzyme is in the DNA gate-open conforma-
tion (Fig. 6b; Dao-Thi et al. 2005), explaining why CcdB
can only act when gyrase is carrying out strand-passage
reactions (Fig. 6a;S m i t ha n dM a x w e l l2006). Subsequent
structural work with CcdA has shown that the antitoxin
protein, CcdA, has an intrinsically disordered domain and
that the protein binds to two partially overlapping binding
sites in CcdB to relieve its inhibition of gyrase (De Jonge
et al. 2009).
CcdB has a unique mode of action that could, in
principle, be emulated by small molecules that could be
developed as novel antibacterial agents. However, the large
size of CcdB and its extensive contacts with GyrA make
this a challenge. Nevertheless, CcdB derivatives, about half
the size of the native protein, comprising fragments of
CcdB connected by a 6-aminohexanoic acid flexible linker
(Trovatti et al. 2008), have been reported to have
inhibitory activity on gyrase supercoiling and topo IV
relaxation, suggesting that it indeed may be possible to
develop CcdB-derived agents.
ParE
ParE/ParD is another example of a toxin–antitoxin system
where the toxin targets DNA gyrase (Jiang et al. 2002;
Johnson et al. 1996). The ParE toxin is produced by the RK2
plasmid of E. coli and has been shown to inhibit DNA
synthesis and to stabilise the gyrase–DNA cleavage com-
plex. Studies on the ParE2 toxin from Vibrio cholerae have
shown that its mode of inhibition of gyrase is quite distinct in
that it requires ATP and inhibits supercoiling but not
relaxation (Yuan et al. 2010). Moreover, although the
antitoxin ParD2 prevents ParE2 toxicity, it cannot reverse
it. The crystal structure of the ParD–ParE complex from
Caulobacter crescentus has been solved and is found to be a
hetero-tetramer, and the antitoxin (ParD) does not show the
unfolded–folded transition seen with CcdA (Dalton and
Crosson 2010); this was preceded by the determination of
the solution structure of ParD by NMR (Oberer et al. 2007).
There are significant similarities between CcdB and ParE
(including a degree of sequence similarity), suggesting that
ParE could be investigated in a similar way to what has been
carried out with CcdB. ParD possesses features reminiscent
of the exit gate of GyrA (Dalton and Crosson 2010); this
structure could therefore form a useful start point for
modelling the ParE–GyrA interaction.
Pentapeptide repeat proteins: Qnr and MfpA
Pentapeptide repeat proteins (PRPs) are a large (>500)
family of prokaryotic and eukaryotic proteins that contain a
tandemly repeated 5-amino acid motif (Vetting et al. 2006).
Qnr is an example and is involved in plasmid-mediated
fluoroquinolone resistance, originally found in Klebsiella
pneumoniae (Martinez-Martinez et al. 1998). Qnr acts by
protecting DNA gyrase and topoisomerase IV from
quinolones, apparently by binding to the enzyme prior to
the binding of DNA (Tran and Jacoby 2002; Tran et al.
2005a, b). This mode of action was confirmed by the
structure of MfpA, a Qnr homologue from Mycobacterium
tuberculosis, which shows that the protein adopts a ‘DNA-
like’ structure containing a right-handed quadrilateral β-
sheet composed of the pentapeptide repeats (Hegde et
al. 2005). Modelling suggests that this motif could bind to
the A subunit of gyrase, mimicking DNA (Fig. 7). The
structure of a Qnr protein bound to GyrA has not yet been
reported. The structure of a Qnr homologue from
Enterococcus faecalis has also been published (Hegde et
al. 2011) and shows an analogous structure to MfpA.
Another PRP family member is McbG (San Millan et al.
1985), which is encoded on the MccB17-producing
plasmids and confers resistance to MccB17, presumably
by a mechanism similar to Qnr/MfpA.
Although Qnr/Mfp proteins confer protection from
fluoroquinolones, they also inhibit gyrase-catalysed super-
coiling (Hegde et al. 2011; Hegde et al. 2005), presumably
by preventing the binding of the enzyme to DNA, a mode
of action reminiscent of simocyclinones. It is currently
unclear what the physiological role of these proteins is, but
they have an intriguing mode of action, which could
present possibilities for the rational design of novel
antibacterials.
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GyrI (also known as SbmC and YeeB) is an 18-kDa E. coli
protein that binds and inhibits DNA gyrase (Nakanishi et al.
1998). As SbmC, it was originally identified as a factor that
protects cells from MccB17 (Baquero et al. 1995). GyrI
binds to the gyrase holoenzyme (A2B2) with a higher
affinity than to either subunit alone and a short stretch of
eight amino acids from GyrI has also been shown to inhibit
gyrase activity (Nakanishi et al. 1998). GyrI appears to act
by preventing gyrase from binding DNA, thus inhibiting
the enzyme but also protecting it from the action of
MccB17 and CcdB (Chatterji and Nagaraja 2002). GyrI
has been found to impart partial protection from quinolones
and also negate the effects of the alkylating agents
mitomycin C and N-methyl-N-nitroso-N′-nitroguanidine
(Chatterji et al. 2003). A crystal structure of GyrI is
available (Romanowski et al. 2002), but this does not
give a clear idea of its molecular mode of action.
However, the fact that peptides derived from GyrI also
inhibit gyrase suggests that it ought to be possible to
generate small molecules that emulate its activity.
Glutamate racemase (MurI) is an enzyme that converts
L-glutamate to D-glutamate, which is an important step in
bacterial cell wall synthesis; MurI was found to be an
inhibitor of E. coli DNA gyrase (Ashiuchi et al. 2002). In
Bacillus subtilis, there are two glutamate racemase
enzymes, Glr and YrpC, and only YrpC was found to be
a gyrase inhibitor (Ashiuchi et al. 2003). MurI proteins
from M. tuberculosis and Mycobacterium smegmatis have
also been shown to inhibit gyrase (Sengupta et al. 2008;
Sengupta and Nagaraja 2008a; Sengupta et al. 2006) and
over-expression protects cells from the action of the
fluoroquinolone ciprofloxacin. Studies with mutants have
shown that the racemisation and gyrase inhibitory functions
of MurI are independent (Sengupta et al. 2008). It is not
really clear why MurI has evolved this ‘moonlighting’
function of inhibiting gyrase, but it may provide new ideas
for the development of antibacterials.
YacG isa small (∼7 kDa)proteinfromE. coli that contains
a zinc-binding motif, which has been shown to inhibit gyrase
by preventing DNA binding (Sengupta and Nagaraja 2008b);
it does not affect topo IVor topo I. YacG acts by binding to
the C-terminal domain of GyrB. Its 3-D structure has been
determined by NMR (Ramelot et al. 2002).
Summary and perspectives
Fluoroquinolones have been the most successful
antibacterial agents targeted to gyrase, but these com-
pounds have been extensively explored both in terms of
improving spectrum and potency, and overcoming
bacterial resistance, and we may have reached the limits
of what these compounds can provide. Therefore, we
need to develop new types of compound and explore
new modes of action. It is clear from the foregoing
discussion that gyrase provides ample opportunities to
develop new antibacterial agents. Screening chemical
libraries has yielded new synthetic entities with gyrase-
inhibiting properties, but it remains to be seen whether
this approach and the compounds generated will achieve
clinical success. Nonetheless, they introduce the possi-
bilities of new scaffolds to explore in terms of new
antibacterial drugs. A variety of natural products, small
molecules and protein-based entities, have been identi-
fied as gyrase inhibitors. These are not generally directly
usable as drugs, due to reasons such as toxicity and poor
physicochemical properties, but they provide chemical
diversity that is not readily achievable using chemical
synthesis; they can also reveal novel modes of mecha-
nism of inhibition of the enzyme. It seems that in our
race to combat drug-resistant bacterial pathogens, the
exploitation of DNA gyrase as an antibacterial target
provides diverse and realistic possibilities.
Fig. 7 MfpA complexed with GyrA (Hegde et al. 2005). The MfpA
protein (green) is shown docked into the structure of the E. coli GyrA
N-terminal domain. Upper: side view; lower: top view (reproduced
with permission from AAAS; Hegde et al. 2005)
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